Back to Search
Start Over
[Abiraterone acetate(ZYTIGA®)-development and literature review].
- Source :
-
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2014 Jul; Vol. 41 (7), pp. 811-6. - Publication Year :
- 2014
-
Abstract
- Abiraterone acetate(AA)has been approved in more than 80 countries for the treatment of patients with metastatic castration-resistant prostate cancer(mCRPC). In July 2013, a marketing approval application for AA was submitted to the Japanese Ministry of Health, Labour, and Welfare. AA is a selective inhibitor of CYP17A1, a crucial enzyme for androgen biosynthesis. AA exerts its anti-tumor activity by directly inhibiting androgen production at all three sources, i. e., the testes, adrenal glands, and tumor itself. Data from international phase III studies and phase I and II studies in Japan have indicated that AA improves the overall survival and quality of life(QoL)of patients with mCRPC. Herein, we have summarized the development of AA and the results of important international and local clinical trials in Japan. In addition, the effect of food on AA bioavailability, concomitant steroid use, and liver function test abnormalities have been discussed regarding the appropriate use of AA.
- Subjects :
- Abiraterone Acetate
Androstadienes adverse effects
Androstenes
Androstenols adverse effects
Chemical and Drug Induced Liver Injury
Enzyme Inhibitors adverse effects
Humans
Male
Prostatic Neoplasms, Castration-Resistant enzymology
Androstadienes therapeutic use
Androstenols therapeutic use
Clinical Trials as Topic
Enzyme Inhibitors therapeutic use
Prostatic Neoplasms, Castration-Resistant drug therapy
Steroid 17-alpha-Hydroxylase antagonists & inhibitors
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0385-0684
- Volume :
- 41
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Gan to kagaku ryoho. Cancer & chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 25131865